Goodpasture's syndrome

Kidney International

Volumn 50, Issue 5, 1996, Pages 1753-1766

  Bolton, W Kline ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; GOODPASTURE SYNDROME; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL;

EID: 0001166762     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.495     Document Type: Article

References (90)

1. GOODPASTURE EW: The significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci 158:863-870, 1919
2. STANTON MC, TANGE JD: Goodpasture's syndrome (pulmonary haemorrhage associated with glomerulonephritis). Aust Ann Med 7:132-144, 1958
3. HOLDSWORTH SR, BOYCE N, THOMSON NM, ATKINS RC: The clinical spectrum of acute glomerulonephritis and lung haemorrhage (Goodpasture's syndrome). Q J Med 55:75-86, 1985
4. COHEN AH, GLASSOCK RJ: Anti-GBM glomerulonephritis including Goodpasture's syndrome, in Renal Pathology, edited by TISHER CC, BRENNER BW, Philadelphia, Lippincott, 1989, p 494
5. HUDSON BG: Anti-type IV collagen diseases. The immunologic basis of renal disease: Paradigms for the 21st century: The American Society of Nephrology's Advances in Basic Science Conference, San Diego, CA, 1995
6. JOHNANSSON C, HELLMARK T, WIESLANDER J: One major epitope in Goodpasture's syndrome. J Am Soc Nephrol 4:608, 1993
7. KEFALIDES NA, OHNO N, WILSON CB: Heterogeneity of antibodies in Goodpasture syndrome reacting with type IV collagen. Kidney Int 43:85-93, 1993
8. MATSUKURA H, BUTKOWSKI RJ, FISH AJ: The Goodpasture antigen: Common epitopes in the globular domains of collagen IV. Nephron 64:532-539, 1993
9. BOLTON WK: The role of high dose steroids in nephritic syndromes: The case for aggressive use, in Controversies in Nephrology and Hypertension, edited by NARINS RG, New York, Churchill-Livingstone, 1984, p 421
10. SAVAGE COS, PUSEY CD, BOWMAN C, REES AJ, LOCKWOOD CM: Antiglomerular basement membrane antibody mediated in the British Isles 1980-4. Br Med J 292:301-304, 1986
11. TEAGUE CA, DOAK PB, SIMPSON IJ, RAINER SP, HERDSON PB: Goodpasture's syndrome: An analysis of 29 cases. Kidney Int 13:492-504, 1978
12. BAILEY RR, SIMPSON IJ, LYNN KL, NEALE TJ, DOAK PB, MCGIVEN AR: Goodpasture's syndrome with normal renal function. Clin Nephrol 15:211-215, 1981
13. ZIMMERMAN SW, VARANASI UR, HOFF B: Goodpasture's syndrome with normal renal function. Am J Med 66:163-171, 1979
14. MCPHAUL JJ, DIXON FJ: Characterization of human anti-glomerular basement membrane antibodies eluted from glomerulonephritic kidneys. J Clin Invest 49:308-317, 1990
15. DONAGHY M, REES AJ: Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet 2:1390-1392, 1983
16. WHITWORTH JA, MOREL-MAROGER L, MIGNON F, RICHET G: The significance of extracapillary proliferation. Nephron 16:1-19, 1976
17. EWAN PW, JONES HA, RHODES CG, HUGHES JMB: Detection of intrapulmonary hemorrhage with carbon monoxide uptake: Application in Goodpasture's syndrome. N Engl J Med 295:1391-1396, 1976
18. SEGELMARK M, BUTKOWSKI R, WIESLANDER J: Antigen restriction and IgG subclasses among anti-GBM autoantibodies. Nephrol Dial Transplant 5:991-996, 1990
19. BOLTON WK, STURGILL BC: Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 9:368-375, 1989
20. WALKER JF, WATSON AJ, GARRETT P, CRONIN CJ, BEOGH B, DONOHOE JF, CARMODY M, O'DWYER WF: Goodpasture's syndrome - 7 years experience of two Dublin renal units. Ir Med J 75:328-333, 1982
21. STRUTZ F, NEILSON EG: The role of lymphocytes in the progression of interstitial disease. Kidney Int 45:S105-S110, 1994
22. PETERS DK, REES AJ, LOCKWOOD CM, PUSEY CD: Treatment and prognosis in antibasement membrane antibody-mediated nephritis. Transplant Proc 14:513-521, 1982
23. REES AJ, LOCKWOOD CM: Antiglomerular basement membrane antibody-mediated nephritis, in Diseases of the Kidney, edited by SCHRIER RW, GOTTSCHALK CW, Boston, Little, Brown, 1988, p 2091
24. LOCKWOOD CM, PEARSON TA, REES AJ, EVANS DJ, PETERS DK: Immunosuppression and plasma exchange in the treatment of Goodpasture's syndrome. Lancet 1:711-715, 1976
25. COHEN LH, WILSON CB, FREEMAN RM: Goodpasture syndrome: Recovery after severe renal insufficiency. Arch Intern Med 136:835-837, 1976
26. BERNIS P, HAMELS J, QUOIDBACH A, MAHIEU P, BOUVY P: Remission of Goodpasture's syndrome after withdrawal of an unusual toxin. Clin Nephrol 23:312-317, 1985
27. STRAUCH BS, CHARNEY A, DOCTOROUFF S, KASHGARIAN M: Goodpasture's syndrome with recovery after renal failure. JAMA 229:444, 1974
28. REES AJ, PETERS DK, COMPSTON DAS, BATCHELOR JR: Strong association between HLA DRW2 and antibody mediated Goodpasture's syndrome. Lancet 1:966-968, 1978
29. GLASSOCK RJ: Clinico-pathologic spectrum and therapeutic strategies in "rapidly progressive" glomerulonephritis. Proc Dialysis Transplant Forum 5:109-116, 1975
30. WILKOWSKI MJ, BOLTON WK: Autoantibodies and other autoimmune serologic abnormalities in dialysis patients. Semin Dial 8:226-231, 1995
31. WU MJ, RAJARAM R, SHELP WD, BEIRNE GJ, BURKHOLDER PM: Vasculitis in Goodpasture's syndrome. Arch Pathol Lab Med 104:300-302, 1980
32. WAHLS TL, BONSIB SM, SCHUSTER VL: Coexistent Wegener's granulomatosis and anti-glomerular basement membrane disease. Human Pathol 18:202-205, 1987
33. O'DONOGHUE DJ, SHORT CD, BRENCHLEY C, LAWLER W, BALLARDIE FW: Sequential development of systemic vasculitis and anti-neutrophil cytoplasmic antibodies complicating anti-glomerular basement membrane disease. Clin Nephrol 32:251-255, 1989
34. JAYNE DRW, MARSHALL PD, JONES SJ, LOCKWOOD CM: Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 37:965-970, 1990
35. BOSCH X, MIRAPEIX E, FONT J, BORRELLAS X, RODRIGUEZ R, LOPEZ-SOTO A, INGELMO M, REVERT L: Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 36:107-113, 1991
36. SHORT AK, ESNAULT VL, LOCKWOOD CM: ANCA and anti-GBM antibodies in RPGN. Adv Exp Med Biol 336:441-444, 1993
37. LERNER RA, GLASSOCK RJ, DIXON FJ: The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 126:989-1004, 1967
38. HUDSON BG, WEISLANDER J, WISDOM BJ, NOELKEN ME: Goodpasture syndrome: Molecular architecture and function of basement membrane antigen. Lab Invest 61:256-269, 1989
39. BUTKOWSKI RJ, LANGEVEID JPM, WIESLANDER J, HAMILTON J, HUDSON BG: Localization of the Goodpasture epitope to a novel chain of basement membrane collagen. J Biol Chem 262:7874-7877, 1987
40. 3(IV) chain of basement membrane collagen. J Biol Chem 266:24018-24024, 1991
41. NEILSON EG, KALLURI R, SUN MJ, GUNWAR S, DANOFF T, MARIYAMA M, MYERS JC, REEDERS ST, HUDSON BG: Specificity of Goodpasture autoantibodies for the recombinant noncollagenous domains of human type IV collagen. J Biol Chem 268:8402-8405, 1993
42. SADO Y, NAITO I, AKITA M, OKIGAKI T: Strain specific responses of inbred rats on the severity of experimental autoimmune glomerulonephritis. J Clin Lab Immunol 19:193-199, 1986
43. MCCOY RC, JOHNSON HK, STONE WJ, WILSON CB: Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis. Kidney Int 21:642-652, 1982
44. 3(IV) chain: Evidence from anti-GBM nephritis after renal transplantation. Kidney Int 42:179-187, 1992
45. MILLINER DS, PIERIDES AM, HOLLEY KE: Renal transplantation in Alport's syndrome. Mayo Clin Proc 57:35-43, 1982
46. GOBEL J, OLBRICHT J, OFFNER G, HELMCHEN U, REPP H, KOCH KM, FREI U: Kidney transplantation in Alport's syndrome: Long term outcome and allograft anti-GBM nephritis. Kidney Int 38:299-304, 1992
47. QUÉRIN S, NÖEL LH, GRÜNFELD JP, DROZ D, MATHIEU P, BERGER J, KREIS H: Linear glomerular IgG fixation in renal allografts: incidence and significance in Alport's sydrome. Clin Nephrol 25:134-140, 1986
48. SHAH B, FIRST MR, MENDOZA NC, CLYNE DH, ALEXANDER JW, WIESS MA: Alport's Syndrome: Risk of glomerulonephritis induced by anti-glomerular-basement-membrane antibody after renal transplantation. Nephron 50:34-38, 1988
49. BOLTON WK, INNES DJ, STURGILL BC, KAISER DL: T-cells and macrophages in rapidly progressive glomerulonephritis: Clinicopathologic correlations. Kidney Int 32:869-876, 1987
50. SALANT DJ: Nephrology Forum: Immunopathogenesis of crescentic glomerulonephritis and lung purpura. Kidney Int 32:408-425, 1987
51. BOLTON WK: Mechanisms of glomerular injury: Injury mediated by sensitized lymphocytes. Semin Nephrol 11:285-293, 1991
52. COUSER WG: Rapidly progressive glomerulonephritis: Classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 11:449-464, 1988
53. MAIN IW, NIKOLIC-PATERSON DJ, ATKINS RC: T cells and macrophages and their role in renal injury. Semin Nephrol 12:395-407, 1992
54. STEBLAY RW: Preliminary evidence for the production of nephritis by an autoimmune mechanism, in Inflammation and Diseases of Connective Tissue, edited by MILLS LC, MOYER JH, Saunders, 1961, p 272
55. BOLTON WK, MAY WJ, STURGILL BC: Proliferative glomerulonephritis in rats: A model for autoimmune glomerulonephritis in humans. Kidney Int 44:294-306, 1993
56. SADO Y, OKIGAKI T, TAKAMIYA H, SEND S: Experimental autoimmune glomerulonephritis with pulmonary hemorrhage in rats. The dose-effect relationship of the nephritogenic antigen from bovine glomerular basement membrane. J Clin Lab Immunol 15:199-204, 1984
57. 3 chain of type IV collagen induces autoimmune Goodpasture syndrome. Proc Natl Acad Sci 91:6201-6205, 1994
58. 3 (IV) collagen disease: A model of human Goodpasture syndrome and anti-GBM nephritis. J Am Soc Nephrol 6:833, 1995
59. BOLTON WK, MAY WJ, STURGILL BC, LUO A, FOX PL: Study of EHS type IV collagen lacking Goodpasture's epitope in glomerulonephritis. Kidney Int 47:404-410, 1995
60. SADO Y, KAGAWA M, NAITO I, OKIGAKI T: Properties of bovine nephritogenic antigen that induces anti-GBM nephritis in rats and its similarity to the Goodpasture antigen. Virchows Arch [B] 60:345-351, 1991
61. BOLTON WK, LUO AM, FOX P, MAY WJ, Fox J: Goodpasture's epitope in the development of experimental autoimmune glomerulonephritis in rats. Kidney Int, in press
62. COUSER WG, WALLACE A, MONACO AP, LEWIS EJ: Successful renal transplantation in patients with circulating antibody to glomerular basement membrane: Report of two cases. Clin Nephrol 1:381-388, 1973
63. WILSON CB, DIXON FJ: Antiglomerular basement membrane antibody induced glomerulonephritis. Kidney Int 3:74-89, 1973
64. JOHNSON JP, MOORE J JR, AUSTIN HA III, BALOW JE, ANTONOVYCH TT, WILSON CB: Therapy of anti-glomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine 64:219-227, 1985
65. HIND CRK, LOCKWOOD CM, PETERS DK, PARASKEVAKOU H, EVANS DJ, REES AJ: Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet 1:263-264, 1983
66. BRIGGS WA, JOHNSON JP, TEICHMAN S, YEAGER HC, WILSON CB: Antiglomerular basement membrane antibody-mediated glomerulonephritis and Goodpasture's syndrome. Medicine 58:348-361, 1979
67. BOLTON WK: Treatment of crescentic glomerulonephritis. Nephrology 1:257-268, 1995
68. SIMPSON IJ, DOAK PB, WILLIAMS LC, BLACKLOCK HA, HILL RS, TEAGUE CA, HERDSON PB, WILSON CB: Plasma exchange in Goodpasture's syndrome. Am J Nephrol 2:301-311, 1982
69. BERGREM H, JERVELL J, BRODWALL E, FLATMARK A, MELLBYE O: Goodpasture's syndrome: A report of seven patients including long-term follow-up of three who received a kidney transplant. Am J Med 68:54-58, 1980
70. PUSEY CD, REES AJ, EVANS DJ, PETERS DK, LOCKWOOD CM: Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 40:757-763, 1991
71. FALK RJ, HOGAN S, CAREY TS, JENNETTE JC: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 114:430-431, 1991
72. WILKOWSKI MJ, BOLTON WK: Systemic vasculitis: The biological basis, in The Kidneys, edited by LEROY EC, New York, Marcel Dekker, 1992, p 381
73. JAYNE DR, DAVIES MJ, Fox CJ, BLACK CM, LOCKWOOD CM: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337:1137-1139, 1991
74. NIKOLIC-PATERSON DJ, LAN HY, HILL PA, VANNICE JL, ATKINS RC: Suppression of experimental glomerulonephritis by the interleukin-1 receptor antagonist: Inhibition of intercellular adhesion molecule-1 expression. J Am Soc Nephrol 4:1695-1700, 1994
75. NISHIKAWA K, GUO YJ, MIYASAKA M, TAMATANI T, COLLINS AB, SY MS, MCCLUSKEY RT, ANDRES G: Antibodies to intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 prevent crescent formation in rat autoimmune glomerulonephritis. J Exp Med 177:667-677, 1993
76. LAN HY, NIKOLIC-PATERSON DJ, ZHENG S, VANNICE JL, ATKINS RC: Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int 43:479-485, 1993
77. LAN HY, ZARAMA M: Suppression of experimental crescentic glomerulonephritis by deoxyspergualin. J Am Soc Nephrol 3:1765-1774, 1993
78. ESNAULT VLM, TESTA A, JAYNE DRW, SOULILLOU JP, GUENEL J: Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis. Nephron 65:180-184, 1993
79. 3(IV) collagen antibodies. A potential therapeutic alternative to plasmapheresis. Exp Nephrol, in press
80. BOLTON WK: The nature of clinical trials in nephrology. Kidney Int 42:1061-1069, 1992
81. LEWIS EJ, BUSCH GJ, SCHUR PH: Gamma G globulin subgroup composition of the glomerular deposits in human renal diseases. J Clin Invest 49:1103-1113, 1970
82. BAKIMER R, KRAUSE I, ABU-SHAKARA M, TEPLIZKI-AMITAL H, ISENBERG DA, ALARCON-SEGOVIA D, VILLAREAL GM, SHOENFELD Y: The frequency of a common anti-DNA idiotype (16/6) in different populations of patients with systemic lupus erythematosus. J Rheumatol 18:1035-1037, 1991
83. BUSKILA D, SHOENFELD Y: Anti-DNA idiotypes: Their pathogenic role in autoimmunity. Concepts Immunopathol 8:85-113, 1991
84. SHOENFELD Y, MOZES E: Pathogenic anti-idiotype (16/6 Id) in systemic lupus erythematosus. Rheumatol Int 11:91-93, 1991
85. REES AJ, PETERS DK, AMOS N, WELSH KI, BATCHELOR R: The influence in HLA linked genes on the severity of anti-GBM antibody mediated nephritis. Kidney Int 26:444-447, 1983
86. TURNER N, MASON PJ, BROWN R, Fox M, POVEY S, REES A, PUSEY CD: Molecular cloning of the human Goodpasture antigen demonstrates it to be the A3 chain of Type IV collagen. J Clin Invest 89:592-601, 1992
87. SHEN G, BUTKOWSKI R, CHENG T, WIESLANDER J, KATZ A, CASS J, FISH AJ: Comparison of non-collagenous type IV collagen subunits in human glomerular basement membrane, alveolar basement membrane, and placenta. Connect Tissue Res 24:289-301, 1990
88. STEBLAY RW, RUDOFSKY UH: Experimental autoimmune antiglomerular basement membrane antibody-induced glomerulonephritis. I. The effects of injecting sheep with human homologous or autologous lung basement membranes and complete Freund's adjuvant. Clin Immunol Immunopathol 27:65-80, 1983
89. HUDSON BG, KALLURI R, GUNWAR S, WEBER M, BALLESTER F, HUDSON JK, NOELKEN ME, SARRAS M, RICHARDSON WR, SAUS J, ABRAHAMSON DR, GLICK AD, HARALSON MA, HELDERMAN JH, STONE WJ, JACOBSON HR: The pathogenesis of Alport syndrome involves type IV collagen molecules containing α3 (IV) chain: Evidence from anti-GBM nephritis after renal transplantation. Kidney Int 42:179-187, 1992
90. ATKINS R: Nephrology Forum: Interleukin-1 in crescentic glomerulonephritis. Kidney Int 48:576-586, 1995